Characterization of ATDC in Pancreatic Cancer
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization : University of Michigan–Ann Arbor
Variable analysis
- ATM inhibitor KU55933
- Chk1/2 inhibitor AZD7762
- MK2 inhibitor
- P38 inhibitor SB203580
- ATDC mutants generated using the QuikChange® II XL Site-Directed Mutagenesis Kit
- ATDC knockdown using shRNA in Panc1 and BxPC3 cells
- Stable expression of ATDC in HEK293 cells
- Measured outcomes
- Panc1, Mia PaCa2, and BxPC3 pancreatic ductal adenocarcinoma cell lines
- Human embryonic kidney (HEK293) cell line
- Human keratinocyte HaCat cell line
- Negative control: No additional authentication was performed on the cell lines following receipt.
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!